

Garattini, Livio

Angelo & Angela Valenti - Centre of Health Economics (CESAV), Mario Negri Institute

**Garattini Livio**

1981-1983 M. NEGRI INSTITUTE, MILAN

Research in the pharmaceutical field focused on the economic and political aspects of drugs.

September 1984-July 1985 SOGESS S.R.L., MILAN

Consultant in hospital planning for Lombardy Regional Health Authority, and healthcare reports for Veneto and Friuli-Venezia-Giulia Regional Health Authorities.

September 1985-July 1990 L. BOCCONI UNIVERSITY, MILAN

Research Fellow :

Health-information system (temporary adviser to the Central Service for Health Planning in the Department of Health),

Health care expenditure (research for Confindustria),

Technology assessment (research for Anie-Assobiomedica),

Allocation of financial resources (research for Bolzano province and Marche Regional Health Authority).

Teacher of Health Care Management at the Business School of the University and consultant to

pharmaceutical companies at Ce.R.G.A.S. (Centre for Research in the Management of Health Care).

September 1990-January 1991 KING'S FUND COLLEGE, LONDON

Attendance as observer at Health Care Management Teaching Programmes and subsequently teacher of the same Programmes for the Italian National Health Service (NHS).

February 1991-May 1991 CENTRE FOR HEALTH ECONOMICS, YORK

Literature review of publications on the English NHS.

June 1991-August 1991 ECOLE NATIONALE DE LA SANTE PUBLIQUE, RENNES

Attendance as observer at Health Care Management Teaching Programmes and subsequently teacher of the same programmes for the Italian NHS.

January 1992 CENTRE FOR HEALTH ECONOMICS ANGELO & ANGELA VALENTI

Director of CESAV from its foundation.

MEMBERSHIPS:

CIPE commission member (1994)

EDITORIAL BOARD member of the "Expert Review of Pharmacoeconomics and Outcomes Research".

EDITORIAL BOARD member of "The European Journal of Health Economics"

EDITORIAL BOARD member of "Applied Health Economics and Health Policy"

EDITORIAL BOARD member of "Health Policy"

MAIN ACTIVITIES: Since January 1992 Director of CESAV (CENTRE FOR HEALTH ECONOMICS ANGELO & ANGELA VALENTI) from its foundation.

The Centre is involved in Health Economics and Health Care Management research. CESAV collaborates with public and private institutions or pharmaceutical companies and other health care

organisations (Department of Health, Regional and Local Health Authorities, Hospitals, etc.). Its position as part of the Mario Negri Institute assures high quality input for research programmes requiring clinical evaluation as a first step, and for a multidisciplinary approach.

Areas of Research of the Centre

- “ [Economic Evaluation of Health Care Programmes](#) - Assessment of costs and benefits of alternative health care treatments and programmes; economic evaluation methodology.
- “ [Resource Allocation Models](#) - Definition of criteria for the geographical and functional distribution of physical and financial resources in health care.
- “ [Comparative Health Policy Analysis](#) - Study of foreign health care systems, in order to identify possible innovation for the Italian NHS.
- “ [Services Organisation](#) - Analysis of strengths and weaknesses of organizations delivering health care services.
- “ [Market Analysis](#) - Supply and demand studies of industrial and commercial sectors dealing with health care.

SELECTED PUBLICATIONS:

1. Garattini L, Van de Vooren K, Curto A (2012) "Regional HTA in Italy: promising or confusing?" Health Policy. 108 (2-3): 203- 206
2. Garattini L, Van de Vooren K, Zaniboni A (2013) "Ethics for end-of-life treatments: Metastatic colorectal cancer is one example" Health Policy.109(1):97-103.
3. Van de Vooren K, Curto A, Garattini L (2013) "Optional co-payments on anti-cancer drugs" BMJ 346
4. Garattini L, Van de Vooren K (2013) "Could Co-Payments on drugs help to make the EU health care systems less open to political influence?" The European Journal of Health Economics 14(5):709-13.
5. Garattini L, Curto A, van de Vooren K. "Italian risk-sharing agreements on drugs: are they worthwhile?" (2015) Eur J Health Econ. 16(1):1-3.
6. van de Vooren K, Curto A, Garattini L. "Curing cervical cancer or preventing it: A case of opportunity cost in the long run?" Vaccine.2014;32(51):6867-9.
7. Garattini L, Curto A, Freemantle N. "Personalized medicine and economic evaluation in oncology: all theory and no practice?" Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):733-8.
8. Garattini L, van de Vooren K, Curto A. "Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?" Health Policy. 2015;119(2):212-6.
9. van de Vooren K, Curto A, Freemantle N, Garattini L. "Market-access agreements for anti-cancer drugs." J R Soc Med.2015;108(5):166-70.
10. Garattini L, Curto A, Freemantle N. "Personalized medicine and economic evaluation in oncology: all theory and no practice?" Expert Rev Pharmacoecon Outcomes Res. 2015 9:1-6.
11. Garattini L, Curto A "Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere

Illusions?" *Pharmacoeconomics*. 2016 Oct;34(10):967-9.

12. Garattini L, Curto A, Padula A, Freemantle N. "Real-world evidence in economic evaluations: Really realistic?". *J R Soc Med*. 2016 Nov; 109(11):404-7.

13. Garattini L, Padula A. "Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?" *J R Soc Med*. 2017 Mar;110(3):98-103.

14. Garattini L, Padula A. Immunotherapies for advanced melanoma: as promising as they are expensive? *J R Soc Med*. 2017. doi: 10.1177/0141076817731094.

(last updated 25.09.2017)